Laman UtamaPSTV • NASDAQ
add
Plus Therapeutics Inc
$0.66
Selepas Waktu Dagangan:(0.60%)+0.0039
$0.66
Tutup: 4 Dis, 8:00:00 PTG GMT-5 · USD · NASDAQ · Penafian
Tutup sebelumnya
$0.60
Julat hari
$0.60 - $0.66
Julat tahun
$0.16 - $2.31
Permodalan pasaran
89.54J USD
Bilangan Purata
5.94J
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Sep 2025info | Perubahan T/T |
|---|---|---|
Hasil | 1.40J | -4.05% |
Perbelanjaan pengendalian | 3.44J | 43.64% |
Pendapatan bersih | -4.42J | -53.90% |
Margin untung bersih | -316.61 | -60.40% |
Pendapatan bagi setiap syer | -0.04 | 89.19% |
EBITDA | -4.40J | -22.36% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Sep 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 16.60J | 246.72% |
Jumlah aset | 18.67J | 167.56% |
Jumlah liabiliti | 13.62J | 12.05% |
Jumlah ekuiti | 5.05J | — |
Syer tertunggak | 137.43J | — |
Harga kepada buku | 14.92 | — |
Pulangan pada aset | -77.22% | — |
Pulangan pada modal | -154.14% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Sep 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -4.42J | -53.90% |
Tunai daripada operasi | -2.55J | 30.76% |
Tunai daripada pelaburan | 1.30J | 14,511.11% |
Tunai daripada pembiayaan | 12.31J | — |
Perubahan bersih dalam tunai | 11.06J | 399.70% |
Aliran tunai bebas | -972.25K | 88.40% |
Perihal
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®. Wikipedia
Diasaskan
1996
Ibu pejabat
Tapak web
Pekerja
21
